Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Golden Finance reported that the board of directors of Nasdaq-listed Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock repurchase plan. The company's CEO Amit Kumar said that the decision on Bitcoin is another way of prudent financial management to achieve higher shareholder value. It is reported that Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
VanEck: Three key indicators show that Bitcoin may have further room to rise
VanEck: Reiterates Bitcoin's $180,000 target price remains unchanged
Double positive stimulus, DOGE price surges 17%